Tag Archives: SCCHN

November, 2018

June, 2017

March, 2017

  • 31 March

    Incyte, Merck Provide Details on Collaboration of Epacadostat and Keytruda

    WILMINGTON, Del. & KENILWORTH, N.J.–(BUSINESS WIRE)–Incyte Corporation (Nasdaq:INCY) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced additional details of their clinical development program investigating the combination of epacadostat, Incyte’s investigational oral selective IDO1 enzyme inhibitor, with KEYTRUDA®(pembrolizumab), Merck’s anti-PD-1 therapy, in patients across five …

November, 2016

April, 2016